AEON Biopharma, Inc.(AEON)Earnings, Financials & Key Ratios
AEON•NASDAQ
Price updated Jun 13, 2026
AboutAEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.Show more
- Revenue$0
- EBITDA-$13M-117.4%
- Net Income-$39M-193.4%
- EPS (Diluted)-3.95-105.4%
AEON Key Insights
AEON Biopharma, Inc. (AEON) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AEON posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AEON Price & Volume
AEON Biopharma, Inc. (AEON) stock price & volume — 10-year historical chart
Loading chart...
AEON Growth Metrics
AEON Biopharma, Inc. (AEON) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-135.54%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-101.69%
Return on Capital
10 Years-1685.32%
5 Years-4971.46%
3 Years-
Last Year-
AEON Peer Comparison
AEON Biopharma, Inc. (AEON) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REVB | 3.2M | 1.00 | -0.04 | -107.66% | 0.08 | |||
 NUVL | 9.07B | 123.25 | -21.07 | -42.78% | ||||
 ACTU | 48.33M | 2.02 | -1.91 | -430.93% | 0.05 | |||
 ABBV | 402.8B | 227.73 | 96.09 | 8.57% | 6.91% | 62.15% | ||
 ALNY | 37.74B | 282.85 | 121.39 | 65.19% | 13.46% | 98.29% | 1.62 | |
 INVA | 1.68B | 22.74 | 6.89 | 18.52% | 118.91% | 47.59% | 0.23 | |
 IQV | 30.79B | 181.46 | 23.15 | 5.87% | 8.33% | 22.11% | 2.44 | |
 CRL | 9.03B | 187.51 | -64.44 | -0.85% | -4.59% | -5.66% | 0.95 |
Compare AEON vs Peers
AEON Biopharma, Inc. (AEON) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AEON Income Statement
AEON Biopharma, Inc. (AEON) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 3.36M | 2.52M | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | -24.99% | -100% | - | - | - | - | - |
Cost of Goods Sold | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 19K |
COGS % of Revenue | 0.03% | - | - | - | - | - | - | - |
Gross Profit | 3.36M▲ 0% | 2.52M▼ 25.0% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -19K▲ 0% |
Gross Margin % | 99.97% | 100% | - | - | - | - | - | - |
Gross Profit Growth % | - | -24.97% | -100% | - | - | - | - | - |
Operating Expenses | 57.32M | 18.91M | 65.85M | 48.43M | 348.09M | -72.98M | 12.8M | 18.26M |
OpEx % of Revenue | 1707.54% | 750.83% | - | - | - | - | - | - |
Selling, General & Admin | 46.04M | 11.59M | 11.15M | 13.68M | 19.79M | 13.64M | 12.21M | 12.97M |
SG&A % of Revenue | 1371.37% | 460.17% | - | - | - | - | - | - |
Research & Development | 4.81M | 7.32M | 25.73M | 34.75M | 33.05M | 14.18M | 4.09M | 5.3M |
R&D % of Revenue | 143.4% | 290.67% | - | - | - | - | - | - |
Other Operating Expenses | 6.47M | 0 | 28.97M | 0 | 295.25M | -100.81M | -3.5M | -11K |
Operating Income | -53.97M▲ 0% | -16.39M▲ 69.6% | -65.85M▼ 301.8% | -48.43M▲ 26.5% | -348.09M▼ 618.8% | 72.98M▲ 121.0% | -12.8M▼ 117.5% | -18.28M▲ 0% |
Operating Margin % | -1607.57% | -650.83% | - | - | - | - | - | - |
Operating Income Growth % | - | 69.63% | -301.8% | 26.45% | -618.76% | 120.97% | -117.54% | - |
EBITDA | -53.09M | -15.51M | -65.84M | -48.36M | -347.99M | 73.08M | -12.72M | -18.2M |
EBITDA Margin % | -1581.5% | -616.08% | - | - | - | - | - | - |
EBITDA Growth % | - | 70.78% | -324.44% | 26.55% | -619.56% | 121% | -117.41% | -112.4% |
D&A (Non-Cash Add-back) | 875K | 875K | 3K | 68K | 99K | 97K | 78K | 78K |
EBIT | -48.37M | -16.39M | -36.88M | -48.43M | -52.84M | -27.82M | -16.3M | -18.29M |
Net Interest Income | -6.75M | -15K | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Income | 720K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 7.47M | 15K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 199.64M | -16.52M | 10.21M | -4.13M | -36.55M | -30.98M | -26.42M | -41.83M |
Pretax Income | 145.67M▲ 0% | -32.91M▼ 122.6% | -55.64M▼ 69.0% | -52.56M▲ 5.5% | -384.63M▼ 631.9% | 42.01M▲ 110.9% | -39.22M▼ 193.4% | -60.11M▲ 0% |
Pretax Margin % | 4339.29% | -1307.11% | - | - | - | - | - | - |
Income Tax | 14.64M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 10.05% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | 172.92M▲ 0% | -32.91M▼ 119.0% | -55.64M▼ 69.0% | -52.56M▲ 5.5% | -384.63M▼ 631.9% | 42.01M▲ 110.9% | -39.22M▼ 193.4% | -60.11M▲ 0% |
Net Margin % | 5151.03% | -1307.11% | - | - | - | - | - | - |
Net Income Growth % | - | -119.03% | -69.04% | 5.54% | -631.85% | 110.92% | -193.37% | -135.54% |
Net Income (Continuing) | 160.31M | -32.91M | -55.64M | -52.56M | -384.63M | 42.01M | -39.22M | -60.11M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 1.28M | 5.04M | 11.12M | 17.09M | 0 | 0 | 0 | 0 |
EPS (Diluted) | 1481.04▲ 0% | -547.60▼ 137.0% | -31.73▲ 94.2% | -27.25▲ 14.1% | -4.99▲ 81.7% | 72.93▲ 1561.5% | -3.95▼ 105.4% | -4.97▲ 0% |
EPS Growth % | - | -136.97% | 94.21% | 14.12% | 81.69% | 1561.52% | -105.42% | -101.69% |
EPS (Basic) | 1495.96 | -547.60 | -31.73 | -27.25 | -4.99 | 77.74 | -3.95 | - |
Diluted Shares Outstanding | 92.3K | 91.62K | 1.75M | 1.93M | 77.07M | 575.95K | 9.92M | 12.11M |
Basic Shares Outstanding | 116K | 60K | 1.75M | 1.93M | 77.07M | 575K | 9.92M | 12.11M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
AEON Balance Sheet
AEON Biopharma, Inc. (AEON) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 112.14M | 20.38M | 5.15M | 9.84M | 6.22M | 1.59M | 3.4M | 6.63M |
Cash & Short-Term Investments | 111.75M | 20.17M | 5.13M | 9.75M | 5.16M | 13K | 3.01M | 6.24M |
Cash Only | 6.32M | 20.17M | 5.13M | 9.75M | 5.16M | 13K | 3.01M | 6.24M |
Short-Term Investments | 105.42M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 267K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | 29.03 | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 26K | 92K | 1.06M | 1.58M | 392K | 382K |
Total Non-Current Assets | 2.21M | 838K | 1.28M | 940K | 623K | 1.55M | 2.16M | 2M |
Property, Plant & Equipment | 0 | 0 | 922K | 906K | 594K | 1.52M | 1.21M | 1.13M |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 1.43M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 778K | 838K | 360K | 34K | 29K | 29K | 948K | 871K |
Total Assets | 114.35M▲ 0% | 21.21M▼ 81.4% | 6.44M▼ 69.7% | 10.78M▲ 67.5% | 6.84M▼ 36.5% | 3.14M▼ 54.1% | 5.56M▲ 77.0% | 8.63M▲ 0% |
Asset Turnover | 0.03x | 0.12x | - | - | - | - | - | 0.00x |
Asset Growth % | - | -81.45% | -69.66% | 67.46% | -36.49% | -54.1% | 76.96% | 261.01% |
Total Current Liabilities | 17.5M | 4.2M | 20.8M | 82.57M | 13.05M | 14.15M | 6.9M | 6.67M |
Accounts Payable | 1.02M | 2.03M | 1.19M | 7.8M | 3.39M | 5.91M | 942K | 1.48M |
Days Payables Outstanding | 374.13K | - | - | - | - | - | - | 42.53K |
Short-Term Debt | 14.79M | 0 | 15.6M | 70.87M | 0 | 0 | 0 | 258K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 809K | 1.25M | 1.07M | 1.11M | 943K | 1.07M | 2.87M | 3.1M |
Current Ratio | 6.41x | 4.85x | 0.25x | 0.12x | 0.48x | 0.11x | 0.49x | 0.99x |
Quick Ratio | 6.41x | 4.85x | 0.25x | 0.12x | 0.48x | 0.11x | 0.49x | 0.99x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 162.73M | 220.25M | 209.46M | 198.62M | 146.84M | 17.56M | 53.69M | 18.71M |
Long-Term Debt | 15.16M | 72.16M | 70.76M | 60.43M | 0 | 11.69M | 34.6M | 1.54M |
Capital Lease Obligations | 0 | 0 | 524K | 242K | 0 | 1.15M | 893K | 3.69M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 147.56M | 148.09M | 138.17M | 137.95M | 146.84M | 4.73M | 18.2M | 16.35M |
Total Liabilities | 180.22M | 224.45M | 230.26M | 281.19M | 159.89M | 31.71M | 60.59M | 25.38M |
Total Debt | 29.95M | 72.16M | 86.89M | 131.53M | 278K | 12.96M | 35.74M | 2.63M |
Net Debt | 23.63M | 51.99M | 81.76M | 121.79M | -4.88M | 12.94M | 32.74M | -3.62M |
Debt / Equity | - | - | - | - | - | - | - | -0.16x |
Debt / EBITDA | - | - | - | - | - | 0.18x | - | -0.14x |
Net Debt / EBITDA | - | - | - | - | - | 0.18x | - | 0.20x |
Interest Coverage | -6.48x | -1092.53x | - | - | - | - | - | - |
Total Equity | -65.87M▲ 0% | -203.23M▼ 208.5% | -223.82M▼ 10.1% | -270.41M▼ 20.8% | -153.04M▲ 43.4% | -28.57M▲ 81.3% | -55.03M▼ 92.6% | -16.75M▲ 0% |
Equity Growth % | - | -208.54% | -10.13% | -20.82% | 43.4% | 81.33% | -92.61% | -59.21% |
Book Value per Share | -713.63 | -2218.18 | -127.64 | -140.22 | -1.99 | -49.60 | -5.55 | -1.38 |
Total Shareholders' Equity | -67.15M | -208.27M | -234.94M | -287.5M | -153.04M | -28.57M | -55.03M | -16.75M |
Common Stock | 11K | 11K | 14K | 14K | 4K | 4K | 9K | 10K |
Retained Earnings | -333.73M | -366.65M | -422.28M | -474.84M | -473.6M | -431.6M | -470.82M | -482.61M |
Treasury Stock | -23K | -23K | -23K | -23K | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 1.28M | 5.04M | 11.12M | 17.09M | 0 | 0 | 0 | 0 |
AEON Cash Flow Statement
AEON Biopharma, Inc. (AEON) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -44.73M | -9.46M | -28.43M | -35.58M | -47.83M | -20.29M | -17.31M | -12.04M |
Operating CF Margin % | -1332.29% | -375.73% | - | - | - | - | - | - |
Operating CF Growth % | - | 78.85% | -200.53% | -25.15% | -34.4% | 57.57% | 14.71% | -505.72% |
Net Income | 160.31M | -32.91M | -55.64M | -52.56M | -384.63M | 42.01M | -39.22M | -60.11M |
Depreciation & Amortization | 1.26M | 0 | 3K | 68K | 99K | 97K | 78K | 78K |
Stock-Based Compensation | 5.25M | 4.79M | 5.22M | 5.89M | 0 | 6.25M | 5.32M | 1.58M |
Deferred Taxes | -14.64M | 0 | 1.18M | 4.75M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -196.96M | 17.21M | 19.38M | -3K | 339.45M | -69.35M | 23.46M | 44.84M |
Working Capital Changes | 50K | 1.45M | 1.42M | 6.27M | -2.74M | 706K | -6.94M | 1.57M |
Change in Receivables | -24K | -148K | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | -7.39M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 3.92M | 667K | -898K | 6.61M | -4.59M | 2.52M | -4.97M | 426K |
Cash from Investing | -117.29M | -1.26M | -170K | -306K | 0 | 0 | -4K | 0 |
Capital Expenditures | -1.69M | 0 | -170K | -306K | 0 | 0 | -4K | 0 |
CapEx % of Revenue | 50.46% | - | - | - | - | - | - | - |
Acquisitions | -36.53M | -1.26M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 73.21M | 24.57M | 13.56M | 40.51M | 14M | 15.15M | 20.3M | 7.83M |
Debt Issued (Net) | 9.68M | 25.11M | 15M | 40.51M | 14M | 15M | 0 | 0 |
Equity Issued (Net) | 77.73M | 0 | 0 | 0 | 0 | 147K | 18.51M | 3.62M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -64K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -14.2M | -541K | -1.44M | 0 | 0 | 0 | 1.79M | 4.21M |
Net Change in Cash | -88.8M▲ 0% | 13.84M▲ 115.6% | -15.04M▼ 208.6% | 4.62M▲ 130.7% | -4.59M▼ 199.4% | -5.14M▼ 12.1% | 2.99M▲ 158.2% | -4.2M▲ 0% |
Free Cash Flow | -46.42M▲ 0% | -9.46M▲ 79.6% | -28.6M▼ 202.3% | -35.89M▼ 25.5% | -47.83M▼ 33.3% | -20.29M▲ 57.6% | -17.31M▲ 14.7% | -12.04M▲ 0% |
FCF Margin % | -1382.75% | -375.73% | - | - | - | - | - | - |
FCF Growth % | - | 79.62% | -202.33% | -25.48% | -33.25% | 57.57% | 14.69% | 38.61% |
FCF per Share | -502.91 | -103.26 | -16.31 | -18.61 | -0.62 | -35.23 | -1.74 | -0.99 |
FCF Conversion (FCF/Net Income) | -0.26x | 0.29x | 0.51x | 0.68x | 0.12x | -0.48x | 0.44x | 0.20x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AEON Key Ratios
AEON Biopharma, Inc. (AEON) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | - | - | - | 223.66% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | 94.45% |
| Gross Margin | 100% | - | - | - | - | - | - |
| Net Margin | -1307.11% | - | - | - | - | - | - |
| Debt / Equity | - | - | - | - | - | - | -0.16x |
| Interest Coverage | -1092.53x | - | - | - | - | - | - |
| FCF Conversion | 0.29x | 0.51x | 0.68x | 0.12x | -0.48x | 0.44x | 0.20x |
| Revenue Growth | -24.99% | -100% | - | - | - | - | - |
Related:AEON Dividend History·AEON Revenue History·AEON Price History·AEON P/E History·AEON Financial Ratios·AEON Institutional Holders
AEON Frequently Asked Questions
AEON Biopharma, Inc. (AEON) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
AEON Biopharma, Inc. (AEON) grew revenue by 0.0% over the past year. Growth has been modest.
AEON Biopharma, Inc. (AEON) reported a net loss of $60.1M for fiscal year 2025.
Dividend & Returns
AEON Biopharma, Inc. (AEON) had negative free cash flow of $12.0M in fiscal year 2025, likely due to heavy capital investments.